Novogene Co., Ltd. (SHA:688315)
17.00
+1.99 (13.26%)
Jan 23, 2026, 3:00 PM CST
Novogene Revenue
Novogene had revenue of 540.65M CNY in the quarter ending September 30, 2025, with 3.47% growth. This brings the company's revenue in the last twelve months to 2.17B, up 3.86% year-over-year. In the year 2024, Novogene had annual revenue of 2.11B with 5.45% growth.
Revenue (ttm)
2.17B
Revenue Growth
+3.86%
P/S Ratio
2.80
Revenue / Employee
986.77K
Employees
2,190
Market Cap
6.08B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 2.11B | 109.21M | 5.45% |
| Dec 31, 2023 | 2.00B | 76.47M | 3.97% |
| Dec 31, 2022 | 1.93B | 59.24M | 3.17% |
| Dec 31, 2021 | 1.87B | 376.37M | 25.26% |
| Dec 31, 2020 | 1.49B | -44.80M | -2.92% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Wuhan Hvsen Biotechnology | 1.67B |
| Kexing Biopharm | 1.52B |
| Xiangxue Pharmaceutical | 1.47B |
| Shenzhen Weiguang Biological Products | 1.14B |
| Beijing Bohui Innovation Biotechnology Group | 834.38M |
| R&G PharmaStudies | 789.45M |
| PharmaResources (Shanghai) | 667.47M |
| Lifecome Biochemistry | 587.04M |